[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bclc-stage-c-hepatocellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bclc-stage-c-hepatocellular-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,72,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100614067","phase-2-sbrt-plus-systemic-therapy-vs-systemic-therapy-alone-in-bclc-c-hepatocellular-carcinoma-100614067",false,"NCT07274774","SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma","Systemic Therapy Combined With Stereotactic Body Radiotherapy Versus Systemic Therapy Alone in BCLC Stage C Hepatocellular Carcinoma (SCRATCH): A Prospective, Multicenter, Phase II, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-70 years.\n2. Histologically or clinically diagnosed HCC per national guidelines.\n3. BCLC stage C (CNLC IIIA\u002FIIIB), including PVTT and\u002For extrahepatic metastases amenable to protocol procedures.\n4. Child-Pugh class A or B (score ≤7).\n5. At least one measurable lesion per RECIST 1.1 (criteria specified).\n6. ECOG ≤2.\n7. Expected survival ≥6 months.\n8. Adequate organ function per protocol thresholds.\n9. For experimental arm candidates: active lesion count (when PET-CT used) ≤10.\n10. If prior initial systemic therapy given: intrahepatic disease stable ≥3 months.\n11. Effective contraception from consent through 1 year after treatment end.\n12. Ability to understand and sign consent.\n\nExclusion Criteria:\n\n1. Second primary malignancy (exceptions apply).\n2. Tumor thrombus\u002Fmetastases judged not amenable to radiotherapy.\n3. Prior systemic anticancer therapy for current HCC (prior local therapy permitted per rules).\n4. Severe organ dysfunction precluding treatment.\n5. Uncontrolled comorbidities (e.g., uncontrolled diabetes, active peptic ulcer, severe cardiopulmonary disease).\n6. Active uncontrolled infection or active autoimmune disease requiring systemic therapy.\n7. Significant neurologic dysfunction.\n8. Pregnant or breastfeeding women; no effective contraception.\n9. Known hypersensitivity to planned drugs.\n10. Any other condition making participation unsuitable per investigator.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},184,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC). The primary objective is to compare overall survival (OS) between the two arms. Secondary objectives include progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and incidence and severity of adverse events (AEs). Eligible patients will be randomized 2:1 to an experimental arm (SBRT + systemic therapy) or control arm (systemic therapy alone). Key inclusion criteria include BCLC C disease, Child-Pugh A-B liver function, ECOG ≤2, measurable disease per RECIST 1.1, and stable intrahepatic disease after initial systemic therapy for ≥3 months when applicable. The trial will also include predefined safety monitoring, QoL assessments (EORTC QLQ-C30 and QLQ-HCC18), and exploratory biomarker analyses.",[28,29],"Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma",[31,32,33,34],"hepatocellular carcinoma","BCLC stage C","metastasis","radiotheraphy","RECRUITING","2026-04-27",{"date":38,"type":39},"2026-04-28","ACTUAL",{"date":41,"type":39},"2025-11-30",{"date":43,"type":22},"2028-11-10",{"name":45,"class":46},"Shandong Cancer Hospital and Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100529317","phase-3-infusional-folfox-plus-camrelizumab-and-apatinib-vs-haic-folfox-plus-camrelizumab-and-apatinib-for-advanced-hcc-100529317","NCT06172205","Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","Infusional FOLFOX Plus Camrelizumab and Apatinib Versus HAIC-FOLFOX Plus Camrelizumab and Apatinib for Hepatocellular Carcinoma of BCLC C Stage: A Multi-center Randomized Phase III Trial","Inclusion Criteria:\n\n1. Age 18-75, male or female;\n2. The clinical diagnosis conforms to primary hepatocellular carcinoma (HCC) and the lesion conforms to BCLC stage C.\n3. Child-pugh liver function grading: Grade A or B\n4. Did not received any type of other first-line drugs such as Sorafenib\n5. According to RECIST 1.1 standard, patients have at least one measurable lesion (CT\u002FMRI scan long diameter ≥10mm or CT\u002FMRI scan short diameter ≥15mm for lymph node lesions, and the lesion has not received radiotherapy, freezing or other local treatments);\n6. ECOG PS score 0-2;\n7. Expected survival ≥ 12 weeks;\n8. The function of vital organs meets the following requirements (excluding the use of any blood component and cell growth factor within 14 days): Blood routine:White blood cells count ≥3.0×10\\^9\u002FL Platelet count ≥70×10\\^9\u002FL Hemoglobin ≥80g\u002FL(without blood transfusion); Liver and kidney function: Serum creatinine (SCr) ≤ 1.5 times upper limit of normal value (ULN); Total bilirubin (TBIL) ≤ 3 times the upper limit of normal value (ULN); AST or ALT levels ≤ 3 times the upper limit of normal value (ULN)\n9. Subjects with HBV or HCV infection should receive anti-virus treatment without interfron.\n10. Women of childbearing age should agree to use contraceptives (such as intrauterine devices, contraceptives or condoms) during and within six months of the end of medication;Patients with negative serum or urine pregnancy tests within 7 days prior to study inclusion and who must be non-lactating, and males should agree to use contraceptives during the study period and for 6 months after the end of the study period.\n11. Patients volunteered to participate in this study and signed informed consent; Subjects have good compliance and cooperate with the follow-up.\n\nExclusion Criteria:\n\n1. Have received immunotherapeutic drugs or interferon in the past.\n2. Severe allergic reaction to other monoclonal antibodies, immunotherapy or chemotherapy.\n3. Female subjects with pregnancy or on feeding.\n4. Patients with congenital or acquired immune deficiencies.\n5. Abnormal coagulation function (INR\\>2.0, PT\\>16s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy, and allow preventive use of low-dose aspirin and low-molecular-weight heparin\n6. The patient has suffered from other malignant tumors at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ)\n7. The patient has active infection, fever of unknown origin within 7 days (CTCAE\\>2)\n8. Patients with congenital or acquired immune deficiencies.\n9. Severe coagulation dysfunction (INR \\> 2.0, PT \\> 16s), with a significant tendency to bleed (including but not limited to vomiting blood or passing blood in stool daily within the past 3 months);\n10. Moderate to severe ascites with clinical symptoms that require therapeutic puncture or drainage, or Child-Pugh score \\> 2 (except for cases where imaging shows only a small amount of ascites without clinical symptoms); uncontrolled or moderate to large pleural effusion or pericardial effusion;\n11. Patients are to be excluded if they have a history of gastrointestinal bleeding within 6 months prior to the start of the study treatment, or have a definite tendency for gastrointestinal bleeding, including but not limited to: bleeding-risk or severe esophageal\u002Fgastric varices, locally active ulcerative lesions, or persistently positive fecal occult blood tests.\n12. Occurrence of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the start of study treatment;\n13. Occurrence of thrombotic or embolic events within 6 months prior to the start of study treatment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction, cerebrovascular abnormalities, cerebral aneurysm), pulmonary embolism, etc.;\n14. Major vascular disease within 6 months prior to the start of study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis); severe, unhealed, or dehisced wounds, as well as active ulcers or untreated fractures; Criteria for Discontinuation of Study Treatment\n15. Previous or current presence of central nervous system metastases;\n16. Individuals with a history of substance abuse of psychiatric medications who are unable to quit, or those with mental disorders; or those with brain metastases or hepatic encephalopathy;\n17. According to the judgment of the investigator, the patients with factors that may affect the results of the study or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) need to be treated together, severe laboratory abnormalities, accompanied by family or social factors, which will affect the safety of patients","75 Years",{"count":57,"type":22},262,[59],"PHASE3","This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.",[29,62],"Chemotherapy Effect","2025-11-25",{"date":65,"type":39},"2025-12-03",{"date":67,"type":39},"2023-07-01",{"date":69,"type":22},"2029-07-31",{"name":71,"class":46},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100501526","liver-cancer-and-immunotherapy-in-the-liquid-biopsy-era-100501526","NCT05810402","Liver Cancer and Immunotherapy in the Liquid Biopsy Era","Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY","LILIPSY","Inclusion Criteria:\n\n* Patients of at least 18 years old,\n* Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,\n* The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,\n* Advanced HCC defined by BCLC stages B and C,\n* Patients with oral consent.\n\nExclusion Criteria:\n\n* Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)\n* No personal history of neoplasia in the previous 5 years\n* No personal history of systemic inflammatory diseases\n* No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)\n* No affiliation or non-beneficiary of a Social Security system;\n* Vulnerable persons according to article L1121-6 of the CSP ;\n* Persons of full age who are protected or unable to give their consent according to article L1121-8 of the CSP;\n* Pregnant or breastfeeding women according to article L1121-5 of the CSP.\n* Non-inclusion due to follow-up difficulties (transfer, insufficient motivation, poor compliance, priority associated pathology in care, etc.)",{"count":81,"type":22},60,[83],"NA","The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.\n\nThe main questions it aims to answer are:\n\n* Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency?\n* Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients?\n\nParticipants blood will be collected at several time points.",[28,86,29,87,88],"BCLC Stage B Hepatocellular Carcinoma","Immune Checkpoint Inhibitor","Liquid Biopsy",[28,90,87,88,91],"BCLC Stage B and C","Precision Medicine","2025-07-07",{"date":94,"type":39},"2025-07-10",{"date":96,"type":39},"2023-06-28",{"date":98,"type":22},"2027-05",{"name":100,"class":46},"University Hospital, Montpellier",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100564662","haic-in-combination-with-pd-1-inhibitors-and-lenvatinib-for-intermediate-and-advanced-hcc-after-the-failure-of-systemic-therapy-recommended-by-bclc-100564662","NCT06632093","HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of portal vein tumor thrombus;\n3. Has received previous systemic therapy recommended for HCC by BCLC, and the systemic therapy failed;\n4. Both PD-1inhibitors and Lenvatinib patients received only include marketed drugs but are not limited to HCC approval;\n5. HAIC was performed after the first PD-1 inhibitor\u002F Lenvatinib treatment or before treatment;\n6. Received at least 2 cycles of HAIC；\n7. Has repeated measurable intrahepatic lesions;\n8. Child-Pugh class A or B.\n\nExclusion Criteria:\n\n1. The interval between the failure of systemic therapy and the beginning of combination therapy longer than 3 months;\n2. With other malignant tumors;\n3. Unable to meet criteria of combination timeframe described above.",{"count":109,"type":22},84,"OBSERVATIONAL","The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.",[86,29,113,114,115,116],"Hepatic Arterial Infusion Chemotherapy","Lenvatinib","PD-1","Systemic Therapy","2024-10-06",{"date":119,"type":39},"2024-10-08",{"date":121,"type":39},"2024-09-16",{"date":123,"type":22},"2025-12-30",{"name":125,"class":46},"First Hospital of China Medical University"]